Validation of transcatheter left ventricular electromechanical mapping for assessment of cardiac function and targeted transendocardial injection in a porcine ischemia-reperfusion model.

Ischemic heart disease, despite advances in treatment, remains the major cause of mortality worldwide. NOGA 3D left ventricular electromechanical mapping allows accurate determination of cardiac function and precise identification of sites of injury. In a porcine model of ischemia-reperfusion injury, we validate the use of the NOGA mapping system for assessment of cardiac function along with the Myostar injection catheter for directed delivery of therapeutics to localized target sites in the setting of acute myocardial injury.

[1]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[2]  P. Serruys,et al.  First experience with remote left ventricular mapping and transendocardial cell injection with a novel integrated magnetic navigation-guided electromechanical mapping system. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  K. Kuck,et al.  Percutaneous endocardial injection of erythropoietin: Assessment of cardioprotection by electromechanical mapping , 2006, European journal of heart failure.

[4]  Jeroen J. Bax,et al.  Effect of intramyocardial injection of autologous bone marrow-derived mononuclear cells on perfusion, function, and viability in patients with drug-refractory chronic ischemia. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  Patrick W Serruys,et al.  Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. , 2003, Journal of the American College of Cardiology.

[6]  James T. Willerson,et al.  Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure , 2003, Circulation.

[7]  LiorGepstein,et al.  Online Myocardial Viability Assessment in the Catheterization Laboratory via NOGA Electroanatomic Mapping , 2001 .

[8]  L. Gepstein,et al.  Online Myocardial Viability Assessment in the Catheterization Laboratory via NOGA Electroanatomic Mapping: Quantitative Comparison With Thallium-201 Uptake , 2001, Circulation.

[9]  B. Nowak,et al.  Myocardial viability assessment by endocardial electroanatomic mapping: comparison with metabolic imaging and functional recovery after coronary revascularization. , 2001, Journal of the American College of Cardiology.

[10]  R. Hendel,et al.  Short- and Intermediate-Term Clinical Outcomes From Direct Myocardial Laser Revascularization Guided by Biosense Left Ventricular Electromechanical Mapping , 2000, Circulation.

[11]  J. Isner,et al.  Left Ventricular Electromechanical Mapping to Assess Efficacy of phVEGF165 Gene Transfer for Therapeutic Angiogenesis in Chronic Myocardial Ischemia , 2000, Circulation.

[12]  S M Dillon,et al.  Electroanatomic left ventricular mapping in the porcine model of healed anterior myocardial infarction. Correlation with intracardiac echocardiography and pathological analysis. , 1999, Circulation.

[13]  L Gepstein,et al.  Electromechanical characterization of chronic myocardial infarction in the canine coronary occlusion model. , 1998, Circulation.

[14]  Mun K. Hong,et al.  Comparison between left ventricular electromechanical mapping and radionuclide perfusion imaging for detection of myocardial viability. , 1998, Circulation.

[15]  M. Leon,et al.  Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. , 1998, Circulation.

[16]  L Gepstein,et al.  Hemodynamic evaluation of the heart with a nonfluoroscopic electromechanical mapping technique. , 1997, Circulation.

[17]  Alan D. Lopez,et al.  Mortality by cause for eight regions of the world: Global Burden of Disease Study , 1997, The Lancet.

[18]  L. Gepstein,et al.  A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart. In vitro and in vivo accuracy results. , 1997, Circulation.

[19]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[20]  E. Diethrich,et al.  One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). , 2009, JACC. Cardiovascular interventions.

[21]  M. Gyöngyösi,et al.  Non-fluoroscopic catheter-based endocardial mapping and mapping-guided percutaneous transmyocardial revascularization , 2001 .